[1] 陈文杰,李高峰.非小细胞肺癌的分子靶向治疗研究进展[J].现代肿瘤医学,2017,25(12):1994~1996. [2] Spaht F, Anaersson U, Dahlin A M, et al. Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study [J]. Tumor Biol, 2016, 37(8):11065~11072. [2] Kadota K, Yeh Y C, D'angelo S P, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. [J]. Am Surg Pathol, 2014, 38(8):1118~1127. [3] Yanagawa N, Shiono S, Abiko M, et al. The correlation of the international association for the study of lung cancer (IASLC)/american thoracic society (ATS)/european respiratory society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma[J]. Ann Thorac Surg, 2014, 98(2):453~458. [4] Revannasiddaiah S, Thakur P, Bhardwaj B, et al. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC / ATS / ERS classification[J].Thorac Dis, 2014, 6:502~525. [5] Wen M,Wang X,et al.Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer[J]. Onco Targets and Ther, 2016,9(1):1989~1995. [6] 王旭洲,陈炜生,余英豪.非小细胞肺癌患者EML4-ALK融合基因突变研究[J].中国肺癌杂志,2015,18(2):80~84.
2019, Vol. 25 
冀公网安备13080202000677号